Heart allograft rejection: Detection with breath alkanes in low levels (the HARDBALL study)

被引:87
作者
Phillips, M
Boehmer, JP
Cataneo, RN
Cheema, T
Eisen, HJ
Fallon, JT
Fisher, PE
Gass, A
Greenberg, J
Kobashigawa, J
Mancini, D
Rayburn, B
Zucker, MJ
机构
[1] Menssana Res Inc, Ft Lee, NJ 07024 USA
[2] Newark Beth Israel Med Ctr, Newark, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[5] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA
[6] Columbia Presbyterian Med Ctr, New York, NY 10032 USA
[7] Mt Sinai Med Ctr, Dept Pathol, New York, NY 10029 USA
[8] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA
[9] Penn State Univ, Milton S Hershey Med Ctr, Sch Med, Dept Med, Hershey, PA 17033 USA
[10] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
关键词
D O I
10.1016/j.healun.2003.07.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We evaluated a new marker of heart transplant rejection, the breath methylated alkane contour (BMAC). Rejection is accompanied by oxidative stress that degrades membrane polyunsaturated fatty acids, evolving alkanes and methylalkanes, which are excreted in the breath as volatile organic compounds (VOCs). Methods: Breath VOC samples (n = 1,061) were collected from 539 heart transplant recipients before scheduled endomyocardial biopsy. Breath VOCs were analyzed by gas chromatography and mass spectroscopy, and BMAC was derived from the abundance of C4-C20 alkanes and monomethylalkanes. The "gold standard" of rejection was the concordant set of International Society for Heart and Lung Transplantation (ISHLT) grades in biopsies read by 2 reviewers. Results: Concordant biopsies were: Grade 0, 645 of 1,061 (60.8%); 1A, 197 (18.6%); 1B, 84 (7.9%); 2, 93 (8.8%); and 3A, 42 (4.0%). A combination of 9 VOCs in the BMAC identified Grade 3 rejection (sensitivity 78.6%, specificity 62.4%, cross-validated sensitivity 59.5%, cross-validated specificity 58.8%, positive predictive value 5.6%, negative predictive value 97.2%). Site pathologists identified the same cases with sensitivity of 42.4%, specificity 97.0%, positive predictive value 45.2% and negative predictive value 96.7%. Conclusions: A breath test for markers of oxidative stress was more sensitive and less specific for Grade 3 heart transplant rejection than a biopsy reading by a site pathologist, but the negative predictive values of the 2 tests were similar. A screening breath test could potentially identify transplant recipients at low risk of Grade 3 rejection and reduce the number of endomyocardial biopsies.
引用
收藏
页码:701 / 708
页数:8
相关论文
共 31 条
[21]   Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress [J].
Phillips, M ;
Cataneo, RN ;
Greenberg, J ;
Gunawardena, R ;
Naidu, A ;
Rahbari-Oskoui, F .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2000, 136 (03) :243-249
[22]   BREATH TESTS IN MEDICINE [J].
PHILLIPS, M .
SCIENTIFIC AMERICAN, 1992, 267 (01) :74-79
[23]   ALVEOLAR GRADIENT OF PENTANE IN NORMAL HUMAN BREATH [J].
PHILLIPS, M ;
GREENBERG, J ;
SABAS, M .
FREE RADICAL RESEARCH, 1994, 20 (05) :333-337
[24]   BIOACTIVATION OF HALOGENATED HYDROCARBONS BY CYTOCHROME-P4502E1 [J].
RAUCY, JL ;
KRANER, JC ;
LASKER, JM .
CRITICAL REVIEWS IN TOXICOLOGY, 1993, 23 (01) :1-20
[25]   CYTOCHROME-P-450 OXIDATION OF ALKANES ORIGINATING AS SCISSION PRODUCTS DURING LIPID-PEROXIDATION [J].
REMMER, H ;
HINTZE, T ;
FRANK, H ;
MUHZANGE, M .
XENOBIOTICA, 1984, 14 (1-2) :207-219
[26]   Oxidative stress in the human heart is associated with changes in the antioxidative defense as shown after heart transplantation [J].
Schimke, I ;
Schikora, M ;
Meyer, R ;
Dübel, HP ;
Modersohn, D ;
Kleber, FX ;
Baumann, G .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2000, 204 (1-2) :89-96
[27]  
SOBOTKA PA, 1994, J HEART LUNG TRANSPL, V13, P224
[28]  
*SPSS, 1998, SPSS WIND STAND VERS
[29]  
Stein D, 2001, CIRCULATION, V104, P81
[30]   P450 3A ACTIVITY AND CYCLOSPORINE DOSING IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS [J].
TURGEON, DK ;
LEICHTMAN, AB ;
LOWN, KS ;
NORMOLLE, DP ;
DEEB, GM ;
MERION, RM ;
WATKINS, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :253-260